Nursing interventions for HbA1c are central to effective diabetes management across primary and secondary care settings. HbA1c, or glycated haemoglobin, reflects average blood glucose levels over two to three months and is the key biomarker used to guide treatment decisions, monitor glycaemic control, and reduce the risk of long-term complications. Nurses are uniquely positioned to assess results, deliver structured education, optimise medicines, and coordinate referrals within the multidisciplinary team. This article outlines evidence-based, NICE-aligned nursing interventions to support patients in achieving and maintaining individualised HbA1c targets safely.

Understanding HbA1c and Its Role in Diabetes Management

HbA1c measures average blood glucose over 90–120 days; a result of 48 mmol/mol or above may confirm type 2 diabetes, though repeat testing is required in asymptomatic individuals and HbA1c is unsuitable in several clinical contexts.

Have any more questions about this? Message our pharmaceutical team to get more info →

HbA1c, or glycated haemoglobin, is a key biomarker used to assess long-term glycaemic control in people living with diabetes. When glucose circulates in the bloodstream, it binds irreversibly to haemoglobin within red blood cells, forming HbA1c. Because red blood cells have a lifespan of approximately 90–120 days, the HbA1c measurement reflects average blood glucose levels over the preceding two to three months, making it a far more reliable indicator of glycaemic control than a single fasting glucose reading.

In clinical practice, HbA1c is expressed in millimoles per mole (mmol/mol) in the UK, following the adoption of IFCC standardisation. A result of 48 mmol/mol (6.5%) or above may be used to confirm a diagnosis of type 2 diabetes in appropriate clinical contexts, in line with NICE and WHO guidance. However, several important caveats apply:

• A repeat confirmatory test is usually required in asymptomatic individuals before a diagnosis of type 2 diabetes is made.

• HbA1c is not appropriate for diagnosing diabetes in people with suspected type 1 diabetes or rapid-onset hyperglycaemia, children and young people, during pregnancy, or in those with conditions that affect red cell turnover or haemoglobin structure (see below).

For ongoing management, HbA1c targets are individualised rather than applied uniformly. NICE guidance (NG28 for type 2 diabetes; NG17 for type 1 diabetes) recommends:

• 48 mmol/mol for people with type 2 diabetes managed by lifestyle measures or metformin alone

• 53 mmol/mol for people on treatments that carry a risk of hypoglycaemia (e.g., sulphonylureas, insulin)

• Higher targets may be appropriate for frail or elderly patients, or those with limited life expectancy, where the risks of tight glycaemic control outweigh the benefits

Elevated HbA1c is associated with an increased risk of microvascular and macrovascular complications, including:

• Retinopathy — damage to the blood vessels of the retina

• Nephropathy — progressive kidney disease

• Peripheral neuropathy — nerve damage, particularly in the feet

• Cardiovascular disease — including myocardial infarction and stroke

Understanding the physiological basis of HbA1c enables nurses to communicate its significance clearly to patients and to contextualise results within a broader picture of diabetes care. It is not merely a number — it is a window into a patient's metabolic health over time.

How Nurses Assess and Monitor HbA1c Levels

Nurses monitor HbA1c every 3–6 months for unstable patients and every 6 months for those at target; point-of-care testing devices require robust quality governance and must not be used for diagnosis unless formally validated.

Nurses play a central role in the assessment and monitoring of HbA1c, both in primary care settings such as GP surgeries and community clinics, and in secondary care environments including diabetes specialist units. The assessment process begins with a thorough clinical review, incorporating the patient's medical history, current medications, comorbidities, and any recent changes in lifestyle or health status that may influence glycaemic control.

HbA1c testing for diagnostic purposes should be performed using a laboratory-based method. Point-of-care testing (POCT) devices — such as the Afinion or DCA Vantage analysers — are used primarily for monitoring in community and primary care settings, providing near-immediate results during consultations. POCT devices should not be used for diagnosis unless they have been formally validated to laboratory standards and are operating under robust POCT governance arrangements, including internal quality control (IQC) and participation in an external quality assurance (EQA) scheme such as UK NEQAS. Nurses operating POCT devices must be trained and competent in their use, and ensure devices are subject to regular quality control checks in line with local laboratory and MHRA guidance.

Monitoring frequency should be tailored to the individual:

• Every 3–6 months for patients whose treatment has recently changed or whose HbA1c is above target

• Every 6 months for patients who are stable and meeting their agreed target

• More frequently if there are concerns about hypoglycaemia, intercurrent illness, or significant lifestyle changes

It is important to recognise that HbA1c results can be unreliable or unsuitable in certain clinical conditions, including:

• Haemolytic anaemia, haemoglobinopathies (e.g., sickle cell disease, thalassaemia)

• Recent blood transfusion or acute blood loss

• Iron, vitamin B12, or folate deficiency

• Advanced chronic kidney disease (CKD stage 4/5)

• Erythropoietin (EPO) therapy

• Pregnancy

In these circumstances, nurses should flag the limitation to the responsible clinician and consider alternative markers. Fructosamine may be used where HbA1c is unreliable; in type 1 diabetes or where HbA1c is consistently unreliable, continuous glucose monitoring (CGM) and time-in-range metrics offer a valuable complementary assessment of glycaemic control. Accurate documentation of results and trends over time is essential for continuity of care.

Evidence-Based Nursing Interventions to Support HbA1c Targets

Nurse-led interventions including medicines optimisation, structured self-monitoring support, and motivational interviewing significantly improve glycaemic outcomes; SGLT-2 inhibitors and insulin require specific safety counselling aligned with MHRA guidance.

Nursing interventions for HbA1c management extend well beyond blood testing. Evidence consistently demonstrates that structured, nurse-led interventions can significantly improve glycaemic outcomes in people with type 1 and type 2 diabetes. These interventions are most effective when they are personalised, culturally sensitive, and delivered within a supportive therapeutic relationship.

Medication management is a cornerstone of nursing practice in this area. Nurses with prescribing qualifications — or working in collaboration with prescribers — can review and optimise antidiabetic regimens. This includes ensuring adherence to oral agents such as metformin, SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin), and GLP-1 receptor agonists (e.g., semaglutide, liraglutide), as well as supporting patients on insulin therapy with dose titration and injection technique review. Each of these drug classes has a distinct mechanism of action and adverse effect profile that nurses must understand:

• Metformin reduces hepatic glucose output; common side effects include gastrointestinal upset. Nurses should be aware that temporary withholding may be required in certain clinical situations — for example, when eGFR falls below 30 mL/min/1.73 m², during acute illness with risk of dehydration, or peri-procedurally when iodinated contrast media is used and there is a risk of acute kidney injury. Decisions should follow the metformin Summary of Product Characteristics (SmPC) and local radiology or medicines policy.

• SGLT-2 inhibitors promote urinary glucose excretion; the most commonly reported adverse effects are genital mycotic infections (thrush). Patients should also be counselled regarding the MHRA-issued warnings on the risk of euglycaemic diabetic ketoacidosis (DKA), which can occur even when blood glucose is not markedly elevated. SGLT-2 inhibitors should be temporarily withheld during acute illness, significant surgical procedures, and prolonged fasting, in line with MHRA guidance and local sick-day rules. Nurses should ensure patients understand when to stop the medication and when to seek urgent review.

• GLP-1 receptor agonists stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite, often supporting weight loss. Nausea and gastrointestinal upset are common initial side effects; patients should be advised these typically improve over time. Nurses should refer to the relevant SmPC for full adverse effect and contraindication information.

• Sulphonylureas and insulin carry a significant risk of hypoglycaemia. Patients prescribed these agents must receive education on recognising and managing hypoglycaemia, including when to seek urgent medical attention.

Nurses and patients should be aware that suspected adverse drug reactions can be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).

Structured self-monitoring support is another key intervention. Nurses can help patients interpret blood glucose readings, identify patterns, and make informed adjustments. Motivational interviewing techniques have been shown to improve engagement and self-efficacy. Additionally, telephone and digital follow-up — increasingly embedded within NHS diabetes services — allows nurses to maintain regular contact between face-to-face appointments, supporting adherence and early identification of deterioration.

Patient Education and Lifestyle Guidance in Clinical Practice

NICE recommends structured education such as DESMOND or DAFNE for all newly diagnosed patients; dietary modification, at least 150 minutes of weekly aerobic exercise, and smoking cessation are key evidence-based lifestyle interventions.

Patient education is one of the most powerful tools available to nurses seeking to support HbA1c improvement. NICE guidance (NG28 for type 2 diabetes; NG17 for type 1 diabetes) strongly recommends that structured education be offered to all people newly diagnosed with diabetes. Programmes such as DESMOND (Diabetes Education and Self-Management for Ongoing and Newly Diagnosed) for type 2 diabetes and DAFNE (Dose Adjustment For Normal Eating) for type 1 diabetes are evidence-based and widely available across NHS services.

Nurses delivering or signposting to education should cover the following key areas:

• Dietary modification — emphasising a balanced diet rich in fibre, low in refined carbohydrates and added sugars, and aligned with individual cultural preferences. Referral to a registered dietitian should be considered where dietary complexity warrants specialist input.

• Physical activity — regular aerobic exercise (at least 150 minutes of moderate-intensity activity per week) has been associated with clinically meaningful reductions in HbA1c in people with type 2 diabetes, with evidence from systematic reviews and meta-analyses (e.g., Umpierre et al.) suggesting reductions in the region of 0.5–0.7% (approximately 5–8 mmol/mol), though the magnitude varies with exercise type, intensity, and baseline control. UK Chief Medical Officers' guidelines also recommend muscle-strengthening activities on at least two days per week.

• Weight management — even modest weight loss of 5–10% of body weight can produce clinically meaningful reductions in HbA1c in people with type 2 diabetes.

• Smoking cessation — smoking worsens insulin resistance and cardiovascular risk; nurses should provide brief advice and refer to NHS Stop Smoking Services.

• Alcohol awareness — excessive alcohol can cause hypoglycaemia, particularly in patients on insulin or sulphonylureas.

Education should be delivered in plain language, avoiding jargon, and adapted to the patient's health literacy level. Written materials, visual aids, and digital resources can reinforce verbal advice. Nurses should signpost eligible patients to the Healthier You: NHS Diabetes Prevention Programme (including its digital delivery options), which offers structured lifestyle interventions for people with non-diabetic hyperglycaemia (HbA1c 42–47 mmol/mol) to prevent progression to type 2 diabetes. Nurses should always check understanding using the teach-back method and document education provided in the patient's care record.

Working Within NHS and NICE Guidelines for HbA1c Management

Nursing practice must align with NICE NG28 and NG17, applying individualised HbA1c targets; nurses should identify patients eligible for the NHS Diabetes Prevention Programme and participate in the National Diabetes Audit.

Nursing interventions for HbA1c must be grounded in current national guidance to ensure safe, consistent, and equitable care. The primary reference documents in England are NICE guideline NG28 (Type 2 diabetes in adults: management), NICE guideline NG17 (Type 1 diabetes in adults: diagnosis and management), and the NHS Long Term Plan, which sets out ambitions for improving diabetes outcomes across the population.

For type 2 diabetes, NICE (NG28) recommends an individualised HbA1c target, typically:

• 48 mmol/mol for patients managed by lifestyle measures or metformin alone

• 53 mmol/mol for patients on drugs that carry a risk of hypoglycaemia (e.g., sulphonylureas, insulin)

• Higher targets may be appropriate for frail or elderly patients, or those with limited life expectancy, where the risks of tight glycaemic control outweigh the benefits

Nurses should be familiar with the Healthier You: NHS Diabetes Prevention Programme (NHS DPP), which targets individuals with non-diabetic hyperglycaemia (HbA1c 42–47 mmol/mol) and offers structured lifestyle interventions — delivered face-to-face and via digital providers — to prevent progression to type 2 diabetes. Identifying and referring eligible patients is an important preventive nursing role.

In terms of prescribing and medicines optimisation, nurses working in advanced practice roles should be aware of relevant MHRA safety guidance. For SGLT-2 inhibitors, this includes warnings regarding euglycaemic DKA and the requirement to withhold these agents during acute illness, significant surgical procedures, and prolonged fasting. For metformin, the decision to withhold peri-procedurally when iodinated contrast is used should follow a risk-based approach aligned with the metformin SmPC and local radiology or medicines policy, taking into account the patient's renal function and AKI risk, rather than a blanket rule.

Audit and quality improvement activity — such as participation in the National Diabetes Audit (NDA) — also falls within the professional remit of nurses working in diabetes care, supporting service-level accountability and continuous improvement.

When to Escalate Care and Refer to the Wider Healthcare Team

Suspected DKA, HHS, or rapidly spreading foot infection require same-day emergency assessment; active diabetic foot disease should be referred to a multidisciplinary foot care service within 24 hours per NICE NG19.

Whilst nurses are well-placed to manage many aspects of HbA1c monitoring and optimisation, recognising the limits of one's scope of practice and escalating appropriately is a fundamental patient safety responsibility. Timely referral to the wider multidisciplinary team (MDT) can prevent complications and ensure patients receive the specialist input they need.

Urgent same-day assessment or emergency referral should be considered when:

• There are symptoms or signs consistent with diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS) — including vomiting, severe dehydration, altered consciousness, or ketonaemia with hyperglycaemia

• There is a rapidly spreading foot infection, wet gangrene, or critical limb ischaemia

Escalation to a GP or diabetes specialist nurse (DSN) should be considered when:

• HbA1c remains persistently above target despite adherence to treatment and lifestyle measures

• There is unexplained deterioration in glycaemic control

• The patient is experiencing recurrent hypoglycaemia or hypoglycaemia unawareness

• There are signs of new or worsening diabetes-related complications (e.g., foot ulceration, visual changes, declining renal function)

• The patient is pregnant or planning pregnancy — glycaemic targets are significantly tighter in this context. Per NICE guideline NG3 (Diabetes in pregnancy), women with diabetes should aim for an HbA1c below 48 mmol/mol before conception if this is safely achievable. Women with an HbA1c above 86 mmol/mol should be advised not to conceive until glycaemic control has improved, given the substantially increased risk of congenital malformation and adverse pregnancy outcomes.

Referral to specialist services may be indicated for:

• Diabetologist or endocrinologist — for complex type 1 diabetes, insulin pump therapy (CSII), or consideration of newer technologies such as continuous glucose monitoring (CGM) or hybrid closed-loop systems

• Dietitian — for complex dietary needs, eating disorders, or renal dietary restrictions

• Multidisciplinary foot care service / foot protection team — for any active diabetic foot problem, NICE guideline NG19 recommends referral within 24 hours for suspected active foot disease (e.g., new ulceration, swelling, discolouration, or infection). Routine high-risk foot assessment should be arranged via the local podiatry or foot protection service.

• NHS Diabetic Eye Screening Programme (DESP) — all people with diabetes should be enrolled in the DESP for routine retinopathy screening. New or acute visual symptoms (e.g., sudden visual loss, floaters) warrant urgent ophthalmology referral rather than waiting for routine screening.

• Renal team — if eGFR is declining or proteinuria is detected

Nurses should document all escalation decisions clearly and communicate them to the relevant team members in a timely manner. Using structured communication tools such as SBAR (Situation, Background, Assessment, Recommendation) supports safe and effective handover. Ultimately, nursing interventions for HbA1c are most effective when delivered collaboratively, with the patient at the centre of a well-coordinated care team.

Frequently Asked Questions